Incidence of Recall After Procedural Sedation With Propofol in the Emergency Department
NCT ID: NCT02200744
Last Updated: 2015-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
250 participants
OBSERVATIONAL
2014-04-30
2017-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Target-controlled Infusion With Propofol in the Emergency Department : a Prospective Study on 45 Adult Patients
NCT03783494
Ketamine-propofol Versus Ketamine Alone for Procedural Sedation in Adults
NCT01544725
Procedural Sedation and Analgesia for Treatment of Adults With Fractures and Dislocations in the Emergency Department
NCT07314450
Pupilometric Evaluation of Patients Under Procedural Sedation With Propofol
NCT05750485
Propofol Target-Controlled Infusion in Emergency Department Sedation
NCT03442803
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary outcome measure will be the recall incidence 2 hours (+/- 15 minutes) after a procedural sedation. A secondary outcome will be the recall incidence one day after the procedural sedation.
The recall will be defined by a positive answer to the third question of the Sandin form (Lancet. 2000;355(9205):707-11).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dislocation reduction using propofol
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who received an initial injection of Propofol by slow intravenous injection of 1 mg/kg in 20 seconds
* Inclusion less than 2 hours from the injection of Propofol
* Patients who have signed a consent to participate in the study
* Patients covered by social security.
Exclusion Criteria
* Patients who cannot signed the informed consent
* Patients who had procedural sedation using other drugs that propofol
* Participation in another study type biomedical research
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de la Réunion
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre-Jean Marianne, MD
Role: PRINCIPAL_INVESTIGATOR
CHU de La Réunion
Marc Weber, MD
Role: PRINCIPAL_INVESTIGATOR
Groupe Hospitalier Est Réunion
Katia Mougin, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Gabriel Martin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Groupe Hospitalier Est Réunion
Saint-Benoît, La Réunion, France
CHU de la Réunion
Saint-Denis, La Réunion, France
Centre Hospitalier Gabriel Martin
Saint-Paul, La Réunion, France
CHU de La Réunion
Saint-Pierre, La Réunion, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marc Weber, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-003669-32
Identifier Type: OTHER
Identifier Source: secondary_id
2013/CHU/08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.